BR112018000933A2 - métodos de tratamento de um distúrbio de desenvolvimento - Google Patents
métodos de tratamento de um distúrbio de desenvolvimentoInfo
- Publication number
- BR112018000933A2 BR112018000933A2 BR112018000933A BR112018000933A BR112018000933A2 BR 112018000933 A2 BR112018000933 A2 BR 112018000933A2 BR 112018000933 A BR112018000933 A BR 112018000933A BR 112018000933 A BR112018000933 A BR 112018000933A BR 112018000933 A2 BR112018000933 A2 BR 112018000933A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- methods
- developmental disorder
- developmental
- disorder
- Prior art date
Links
- 208000012239 Developmental disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562193717P | 2015-07-17 | 2015-07-17 | |
US201562207595P | 2015-08-20 | 2015-08-20 | |
US201662332567P | 2016-05-06 | 2016-05-06 | |
US201662346763P | 2016-06-07 | 2016-06-07 | |
US15/209,862 US20170014393A1 (en) | 2015-07-17 | 2016-07-14 | Methods of treating developmental disorders with gaboxadol |
PCT/US2016/042238 WO2017015049A1 (en) | 2015-07-17 | 2016-07-14 | Methods of treating developmental disorders with gaboxadol |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018000933A2 true BR112018000933A2 (pt) | 2018-09-04 |
Family
ID=57774846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018000933A BR112018000933A2 (pt) | 2015-07-17 | 2016-07-14 | métodos de tratamento de um distúrbio de desenvolvimento |
Country Status (16)
Country | Link |
---|---|
US (8) | US20170014393A1 (pt) |
EP (1) | EP3324961A4 (pt) |
JP (3) | JP2018520189A (pt) |
KR (1) | KR20180031721A (pt) |
CN (2) | CN116531370A (pt) |
AU (2) | AU2016295138B2 (pt) |
BR (1) | BR112018000933A2 (pt) |
CA (1) | CA2992734A1 (pt) |
CL (1) | CL2018000142A1 (pt) |
CO (1) | CO2018000375A2 (pt) |
HK (1) | HK1250951A1 (pt) |
IL (2) | IL256912B2 (pt) |
MX (2) | MX2018000745A (pt) |
PE (2) | PE20190338A1 (pt) |
TW (2) | TWI819995B (pt) |
WO (1) | WO2017015049A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3372229T (pt) | 2014-06-06 | 2021-06-17 | Ovid Therapeutics Inc | Métodos para aumentar a inibição tónica e tratar a síndrome de angelman |
PE20190338A1 (es) | 2015-07-17 | 2019-03-07 | Ovid Therapeutics Inc | Metodos de tratamiento de trastornos del desarrollo con gaboxadol |
MX2019001669A (es) | 2016-08-11 | 2019-09-27 | Ovid Therapeutics Inc | Metodos y composiciones para el tratamiento de trastornos epilepticos. |
CN110225754A (zh) * | 2016-11-22 | 2019-09-10 | 奥维德医疗公司 | 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法 |
US10071083B2 (en) * | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
AU2018309049A1 (en) | 2017-08-04 | 2020-02-27 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
CN112739353A (zh) * | 2018-06-14 | 2021-04-30 | 奥维德医疗公司 | Mir-92a或mir-145在治疗安格曼综合征中的用途 |
KR20210049855A (ko) * | 2018-08-22 | 2021-05-06 | 오비드 테라퓨틱스 인크. | 위장관 장애들 및 천식의 치료에서 가복사돌의 사용 |
US10765666B2 (en) | 2018-09-20 | 2020-09-08 | Ovid Therapeutics Inc | Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering |
WO2020106976A1 (en) * | 2018-11-21 | 2020-05-28 | Certego Therapeutics | Combination of gaboxadol and lithium for the treatment of psychiatric disorders |
US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
CN113423399A (zh) | 2018-12-17 | 2021-09-21 | 奥维德医疗公司 | 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途 |
AU2020288999A1 (en) * | 2019-06-07 | 2022-02-03 | Paxmedica, Inc. | Compositions and methods for treating central nervous system disorders |
CN114173765A (zh) * | 2019-07-15 | 2022-03-11 | 奥维德医疗公司 | 用于治疗性治疗的包含加波沙朵的药物制剂 |
MX2022007715A (es) | 2019-12-18 | 2022-07-19 | Ovid Therapeutics Inc | Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36. |
AU2021275863A1 (en) | 2020-05-20 | 2023-02-02 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2830083A (en) | 1953-04-29 | 1958-04-08 | Allied Chem & Dye Corp | Production of aryloxy aliphatic carboxylic acids |
US4084000A (en) | 1975-07-16 | 1978-04-11 | Nelson Research And Development Company | Method of treating schizophrenia |
US4138484A (en) | 1976-08-16 | 1979-02-06 | Nelson Research & Development Company | Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs |
US4129652A (en) | 1976-08-16 | 1978-12-12 | Nelson Research & Development Company | Method for potentiating neuroleptic drugs |
DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
DE19526864A1 (de) | 1995-07-22 | 1997-01-23 | Labtec Gmbh | Hormonpflaster |
US6461644B1 (en) | 1996-03-25 | 2002-10-08 | Richard R. Jackson | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods |
US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
AU2002227052A1 (en) * | 2000-11-30 | 2002-06-11 | University Of Florida | Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
US6676961B1 (en) | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
GB0402118D0 (en) * | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
KR20070010136A (ko) * | 2004-04-02 | 2007-01-22 | 하. 룬트벡 아크티에 셀스카브 | 가복사돌을 이용한 손상된 호흡 기능의 치료 |
JP2007530604A (ja) | 2004-04-02 | 2007-11-01 | ハー・ルンドベック・アクチエゼルスカベット | 呼吸機能障害の治療 |
GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
US20070112017A1 (en) * | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20110046090A1 (en) | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
JP2010510314A (ja) * | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス,エルエルシー | 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法 |
WO2008095221A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
US20090143335A1 (en) * | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
EP2334299A1 (en) * | 2008-09-01 | 2011-06-22 | H. Lundbeck A/S | Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat |
CN102147667A (zh) | 2010-02-08 | 2011-08-10 | 深圳富泰宏精密工业有限公司 | 触控笔 |
WO2012050907A2 (en) | 2010-09-28 | 2012-04-19 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
WO2012075286A2 (en) | 2010-12-01 | 2012-06-07 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
EP3108876A1 (en) | 2011-10-13 | 2016-12-28 | Jaleva Pharmaceuticals LLC | Methods and compositions for rapid transbuccal delivery of active agents |
JP2016501876A (ja) * | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
WO2014123909A1 (en) | 2013-02-05 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Positive allosteric modulators of the gaba-a receptor in the treatment of autism |
PT3372229T (pt) | 2014-06-06 | 2021-06-17 | Ovid Therapeutics Inc | Métodos para aumentar a inibição tónica e tratar a síndrome de angelman |
JP6491679B2 (ja) | 2014-06-12 | 2019-03-27 | ファイザー・リミテッドPfizer Limited | Gabaa受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体 |
US20170348232A1 (en) | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
PE20190338A1 (es) | 2015-07-17 | 2019-03-07 | Ovid Therapeutics Inc | Metodos de tratamiento de trastornos del desarrollo con gaboxadol |
US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
EP3334427A4 (en) | 2015-08-11 | 2019-02-06 | Ovid Therapeutics, Inc. | METHODS OF SEDATION AND PARENTERAL COMPOSITION FOR USE IN INTENSIVE CARE |
US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
MX2019001669A (es) | 2016-08-11 | 2019-09-27 | Ovid Therapeutics Inc | Metodos y composiciones para el tratamiento de trastornos epilepticos. |
US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
-
2016
- 2016-07-14 PE PE2018000085A patent/PE20190338A1/es unknown
- 2016-07-14 CA CA2992734A patent/CA2992734A1/en active Pending
- 2016-07-14 US US15/209,862 patent/US20170014393A1/en not_active Abandoned
- 2016-07-14 MX MX2018000745A patent/MX2018000745A/es unknown
- 2016-07-14 IL IL256912A patent/IL256912B2/en unknown
- 2016-07-14 JP JP2018502084A patent/JP2018520189A/ja not_active Withdrawn
- 2016-07-14 WO PCT/US2016/042238 patent/WO2017015049A1/en active Application Filing
- 2016-07-14 CN CN202310549878.XA patent/CN116531370A/zh active Pending
- 2016-07-14 BR BR112018000933A patent/BR112018000933A2/pt not_active Application Discontinuation
- 2016-07-14 IL IL305342A patent/IL305342A/en unknown
- 2016-07-14 EP EP16828266.3A patent/EP3324961A4/en active Pending
- 2016-07-14 CN CN201680054308.1A patent/CN108024997A/zh active Pending
- 2016-07-14 PE PE2022002752A patent/PE20230735A1/es unknown
- 2016-07-14 AU AU2016295138A patent/AU2016295138B2/en active Active
- 2016-07-14 KR KR1020187004863A patent/KR20180031721A/ko not_active Application Discontinuation
- 2016-07-15 TW TW105122538A patent/TWI819995B/zh active
- 2016-07-15 TW TW112110413A patent/TW202325293A/zh unknown
-
2017
- 2017-12-13 US US15/840,521 patent/US20180098974A1/en not_active Abandoned
-
2018
- 2018-01-17 CL CL2018000142A patent/CL2018000142A1/es unknown
- 2018-01-17 MX MX2022004734A patent/MX2022004734A/es unknown
- 2018-01-22 CO CONC2018/0000375A patent/CO2018000375A2/es unknown
- 2018-08-02 US US16/053,343 patent/US20180338960A1/en not_active Abandoned
- 2018-08-15 HK HK18110494.0A patent/HK1250951A1/zh unknown
- 2018-12-17 US US16/221,794 patent/US11096929B2/en active Active
-
2019
- 2019-05-01 US US16/400,227 patent/US20190255027A1/en not_active Abandoned
- 2019-06-25 US US16/451,591 patent/US20190321342A1/en not_active Abandoned
-
2020
- 2020-06-25 US US16/911,540 patent/US20210030727A1/en not_active Abandoned
-
2021
- 2021-05-25 JP JP2021087584A patent/JP2021130687A/ja active Pending
- 2021-10-12 AU AU2021250862A patent/AU2021250862B2/en active Active
-
2022
- 2022-11-04 US US17/981,148 patent/US20230071127A1/en active Pending
-
2023
- 2023-05-16 JP JP2023080696A patent/JP2023103375A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018000933A2 (pt) | métodos de tratamento de um distúrbio de desenvolvimento | |
DK3331876T3 (da) | Modulators of ror-gamma | |
MA53943A (fr) | Modulateurs de ror-gamma | |
DK3354729T3 (da) | Anti-garp-antistof | |
DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
MA55328A (fr) | Modulateurs de ror-gamma | |
DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
MA45277A (fr) | Promédicaments de pth | |
DK3341479T3 (da) | LNA-G-Proces | |
ES2864754T8 (es) | Método de producción de metionina | |
DK3163339T3 (da) | Polariseringsbevarende multikernefiber | |
DK3393579T3 (da) | Øjenbehandlingssystem | |
DK3389692T3 (da) | Modulatorer af komplement-aktivitet | |
BR112016018754A2 (pt) | método de tratamento de um câncer com vascularização | |
DK3307267T3 (da) | Behandling af multipel sklerose | |
DK3283210T3 (da) | Fremgangsmåde | |
BR112016023582A2 (pt) | método de tratamento de um material | |
CL2016002165A1 (es) | Compuestos de aminocarbonilcarbamato | |
ES2893126T8 (es) | Métodos de tratamiento de afecciones oculares | |
BR112018000204A2 (pt) | métodos de tratamento de colite | |
DK3385386T6 (da) | Biosyntetisk carrimycin-gencluster | |
BR112016027556A2 (pt) | métodos de preparação de um composto | |
MA46454A (fr) | Procédé multi-protéase | |
DK3259549T3 (da) | Lyssporammunition | |
DK3200783T3 (da) | Behandling af erytromelalgi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |